Physician profile
Kumar P Daulat
NPI 1992847651
$1,275.14
in general payments reported to CMS, 2019-2025
13 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.15 · 2021: $49.61 · 2022: $128 · 2023: $99.99 · 2024: $329 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.48 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $236.14 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $110.37 | 2022-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $98.35 | 2021-2025 | Esprit, Freestyle Libre 2 |
| Pfizer INC. | $93.81 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.90 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $28.79 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $25.74 | 2024 | |
| Nevro Corp. | $24.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.17 | 2024 | |
| Sanofi Pasteur INC. | $22.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Daulat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.